Evaluation of genotype-guided acenocoumarol dosing algorithms in Russian patients

Drug Metabolism and Personalized Therapy
Dmitriy Alexeyevich SychevRuslan Evgenyevich Kazakov

Abstract

Acenocoumarol dose is normally determined via step-by-step adjustment process based on International Normalized Ratio (INR) measurements. During this time, the risk of adverse reactions is especially high. Several genotype-based acenocoumarol dosing algorithms have been created to predict ideal doses at the start of anticoagulant therapy. Nine dosing algorithms were selected through a literature search. These were evaluated using a cohort of 63 patients with atrial fibrillation receiving acenocoumarol therapy. None of the existing algorithms could predict the ideal acenocoumarol dose in 50% of Russian patients. The Wolkanin-Bartnik algorithtm based on European population was the best-performing one with the highest correlation values (r=0.397), mean absolute error (MAE) 0.82 (±0.61). EU-PACT also managed to give an estimate within the ideal range in 43% of the cases. The two least accurate results were yielded by the Indian population-based algorithms. Among patients receiving amiodarone, algorithms by Schie and Tong proved to be the most effective with the MAE of 0.48±0.42 mg/day and 0.56±0.31 mg/day, respectively. Patient ethnicity and amiodarone intake are factors that must be considered when building future algorithms. Furt...Continue Reading

References

Jan 1, 1985·European Journal of Clinical Pharmacology·C RichardP Auzépy
Sep 1, 1984·British Journal of Clinical Pharmacology·M ArboixJ R Laporte
Nov 21, 2008·Pharmacogenomics·Christos N MarkatosAnthi Travlou
Apr 11, 2012·Journal of Clinical Pharmacy and Therapeutics·F Z SmiresS Nadifi
Jun 19, 2013·European Journal of Clinical Pharmacology·Tudor Radu PopAnca Dana Buzoianu
Sep 11, 2013·European Journal of Clinical Pharmacology·Dhakchinamoorthi Krishna KumarChandrasekaran Adithan
Jun 24, 2014·Pharmacogenomics·Juan Jose Cerezo-ManchadoRocio Gonzalez-Conejero
Dec 19, 2014·European Journal of Clinical Pharmacology·Dhakchinamoorthi Krishna KumarChandrasekaran Adithan
May 31, 2015·Blood·Nita A LimdiT Mark Beasley
Dec 15, 2016·Pharmacogenomics·Georgia RagiaVangelis G Manolopoulos

❮ Previous
Next ❯

Methods Mentioned

BETA
electrophoresis

Software Mentioned

PACT
PrimerSelect
EU

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.